Trial Profile

A Phase 1b Study of the Selective HDAC6 Inhibitor ACY-241 in Combination With Nivolumab in Patients With Unresectable Non-Small Cell Lung Cancer

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 09 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Citarinostat (Primary) ; Nivolumab (Primary)
Indications Adenocarcinoma; Non-small cell lung cancer
Focus Adverse reactions
Sponsors Acetylon Pharmaceuticals; Celgene Corporation

Most Recent Events

06 May 2024 Status changed from active, no longer recruiting to discontinued. (Lack of efficacy)
03 Jan 2024 Planned End Date changed from 30 Jun 2023 to 31 Jan 2024.
03 Jan 2024 Planned primary completion date changed from 30 Jun 2023 to 31 Jan 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com